1. Home
  2. AGEN

as 10-09-2025 3:51pm EST

$
-
.
-
-
+
$
-
.
-
-
+
-
.
-
-
%

Stocks

Health Care

Biotechnology: Biological Products (No Diagnostic Substances)

Nasdaq

Agenus Inc is an American clinical-stage company with a pipeline of therapies designed to activate the body's immune system to fight cancer and infections, including immune-modulatory antibodies, adoptive cell therapies through its subsidiary MiNK Therapeutics Inc. and vaccine adjuvants through its subsidiary SaponiQx Inc. This robust product pipeline is supported by company's in-house capabilities, including current good manufacturing practice (cGMP) manufacturing and a clinical operations platform. The company's antibody candidates are botensilimab (a proprietary next-generation Fc-engineered CTLA-4 antibody, also known as AGEN1811) and balstilimab (a PD-1 antibody).

Founded: 1994 Country:
United States
United States
Employees: N/A City: LEXINGTON
Market Cap: 142.8M IPO Year: 2000
Target Price: $14.50 AVG Volume (30 days): 431.2K
Analyst Decision: Buy Number of Analysts: 2
Dividend Yield:
N/A
Dividend Payout Frequency: N/A
EPS: -6.83 EPS Growth: N/A
52 Week Low/High: $1.38 - $7.34 Next Earning Date: 11-11-2025
Revenue: $101,706,000 Revenue Growth: -36.29%
Revenue Growth (this year): 60.49% Revenue Growth (next year): -19.74%

AGEN Daily Stock ML Predictions

Share on Social Networks: